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Abstract
Heparin has been shown to regulate human neutrophil elastase (HNE) activity. We have assessed the regulatory effect of
heparin on Tissue Inhibitor of Metalloproteases-1 [TIMP-1] hydrolysis by HNE employing the recombinant form of TIMP-1
and correlated FRET-peptides comprising the TIMP-1 cleavage site. Heparin accelerates 2.5-fold TIMP-1 hydrolysis by HNE.
The kinetic parameters of this reaction were monitored with the aid of a FRET-peptide substrate that mimics the TIMP-1
cleavage site in pre-steady-state conditionsby using a stopped-flow fluorescence system. The hydrolysis of the FRET-peptide
substrate by HNE exhibits a pre-steady-state burst phase followed by a linear, steady-state pseudo-first-order reaction. The
HNE acylation step (k2=2161s
21) was much higher than the HNE deacylation step (k3=0.5760.05 s
21). The presence of
heparin induces a dramatic effect in the pre-steady-state behavior of HNE. Heparin induces transient lag phase kinetics in
HNE cleavage of the FRET-peptide substrate. The pre-steady-state analysis revealed that heparin affects all steps of the
reaction through enhancing the ES complex concentration, increasing k1 2.4-fold and reducing k21 3.1-fold. Heparin also
promotes a 7.8-fold decrease in the k2 value, whereas the k3 value in the presence of heparin was increased 58-fold. These
results clearly show that heparin binding accelerates deacylation and slows down acylation. Heparin shifts the HNE pH
activity profile to the right, allowing HNE to be active at alkaline pH. Molecular docking and kinetic analysis suggest that
heparin induces conformational changes in HNE structure. Here, we are showing for the first time that heparin is able to
accelerate the hydrolysis of TIMP-1 by HNE. The degradation of TIMP-1is associated to important physiopathological states
involving excessive activation of MMPs.
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Introduction
Human neutrophil elastase (HNE) is a powerful serine proteinase
secreted by neutrophils, the first cells recruited to inflammatory
sites. HNE is present at concentrations in the milimolar range in the
azurophil granules of neutrophils [1]. HNE is a very basic protein
with a pI .9.0; eighteen arginine residues are arranged to the
surface of the enzyme in a horseshoe-like manner around the active
site [2], they strongly interact with heparin-like glycosaminoglycans
[3,4]. HNE depends on serglycin proteoglycans for localization in
azurophil granules. Serglycin proteoglycan, the major intracellular
proteoglycan of hematopoietic cells, has been related to sorting and
packing of granule proteins [5].
Neutrophil elastase/antielastase imbalance is related to uncon-
trolled proteolytic injury in several chronic inflammatory diseases
[6]. It has been shown that heparin is capable of decreasing the
inhibitory activity of a1-antitrypsin inhibitor and Mucus Proteinase
Inhibitor upon HNE and neutrophil cathepsin G [7].Insputum sols
of patients with bronchiectasis, shed syndecan-1 restricts HNE from
a1-antitrypsin, the interaction of HNE with heparan sulfate
polysaccharide chain lead to unopposed neutrophil elastase activity,
despite overwhelming excess of the physiological antielastase, a1-
antitrypsin inhibitor [8]. Interestingly, cellular heparan sulfate
proteoglycans (HSPG) can anchor HNE at the cell surface of
neutrophils; this interaction preserves the catalytic activity of
HNE upon its natural substrates, fibronectin and elastin [9]. HNE
binding to HSPG at the neutrophil surface focuses the activity of
this potent proteolytic enzyme to the pericellular environment
and also preserves its activity by protecting it from inhibition by
a1-antitrypsin and SLPI [10].
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and syndecan-4 maintain the proteolytic balance in acute wound
fluid. Syndecan-1 ectodomain protects cathepsin G from inhibition
by a1-antichymotrypsin and squamous cell carcinoma antigen 2,
and it protects neutrophil elastase from inhibition by a1-proteinase
inhibitor.Moreover, thedegradation ofendogenousheparansulfate
from wound fluids reduces proteolytic activities in the fluid [11].
Syndecan knockout mice show deficits in tissue repair [12]. Taken
together, these data show that heparan sulfate proteoglycans are
orchestrating the inflammatory response in the process of tissue
repair [13].
TIMP-1 is tightly correlated to the maintenance of extracellular
matrix (ECM) structure, by acting as inhibitor of MMP-2 and
MMP-9. Extracellular matrix degradation is observed in several
physiopathological conditions, such as tumor cell invasion,
arthritis, metastasis and inflammatory processes [14]. It has been
shown that TIMP-1 and MMP-9 activities can be regulated by
HNE activity. HNE preferentially inactivates TIMP-1 in the pro-
MMP-9.TIMP-1 complex and renders pro-MMP-9 activatable by
MMP-3 [15]. HNE was shown to be able to inactivate TIMP-1
through the cleavage of a single peptide bond Val
69-Cys
70 [16].
The activation of MMP-9 and the TIMP-1 inactivation by HNE
have important physiopathological role in cystic fibrosis lung
disease [17], intracranial hemorrhage [18], abdominal aortic
aneurysm [19] and bone resorption [20].
In this study, we have investigated the influence of heparin upon
HNE activity in the inactivation on TIMP-1. A combination of
SDS-PAGE, FRET-peptide substrate assays in stopped-flow
fluorescence kinetic measurements and molecular docking, was
used to characterize the interaction of HNE with heparin. Here,
we are showing for the first time that heparin is able to accelerate
the hydrolysis of TIMP-1 by HNE. The excessive degradation of
TIMP-1is associated to important physiopathological states
involving activation of MMP-9.
Materials and Methods
Materials
HNE (EC 3.4.21.37) was purchased from Calbiochem/Nova-
biochem, (LaJolla, USA). Fluorogenic substrate MeOSuc-AAPV-
MCA, irreversible inhibitor of HNE MeO-Suc-AAPV-CH2Cl and
serine proteinase inhibitor PMSF were purchased from Sigma-
Aldrich (USA). Human recombinant TIMP-1 was prepared as
described previously [21]. Heparin 14 kDa was purchased from
Calbiochem (La Jolla, USA). The Fluorescence Resonance Energy
Transfer (FRET)-peptide containing ortho-aminobenzoic acid
(Abz) as donor group and N-(2,4-dinitrophenyl) ethylenediamine
(EDDnp) as acceptor group, Abz-AMESVMGYFHRSQ-EDDnp
was synthesized in solid phase chemistry as described below.
Chemical Synthesis of FRET-peptide
The Fluorescence Resonance Energy Transfer (FRET)-peptide
substrate containing ortho-aminobenzoic acid (Abz) as donor group
and N-(2,4-dinitrophenyl) ethylenediamine (EDDnp) as acceptor
group, Abz-AMESVMGYFHRSQ-EDDnp was synthesized in
solid phase chemistry as described previously [22]. An automated
bench top simultaneous multiple solid-phase peptide synthesizer
(PSSM 8 system from Shimadzu) was used for solid-phase
synthesis of the FRET-peptide substrate by Fmoc-procedure.
The final deprotected peptides were purified by semi preparative
HPLC using an Econosil C-18 column (10 mm, 22.56250 mm)
and a two solvent system: (A) TFA/H2O (1:1000) and (B) TFA/
acetonitrile (CAN)/H2O (1:90:10). The column was eluted at a
flow rate of 5 mL/min with a 10 (or 30) to 50 (or 60)% gradient of
solvent B over 30 or 45 min. Analytical HPLC was performed
using a binary HPLC system from Shimadzu with SPD-10AV
Shimadzu UV-vis detector and a Shimadzu RF-535 fluorescence
detector, coupled to an Ultrasphere C-18 column (5 mm,
4.66150 mm) which was eluted with solvent systems A and B at
a flow rate of 1 mL/min and 10 to 80% gradient of B over
20 min. The elution of peptides in HPLC column was monitored
by absorbance at 220 nm and by fluorescence emission at 420 nm
following excitation at 320 nm. The molecular weight and purity
of synthesized peptides were checked by MALDI-TOF mass
spectrometry (TofSpec-E, Micromass) and/or peptide sequencing
using a protein sequencer PPSQ-23 (Shimadzu Tokyo, Japan).
Kinetic Studies
HNEendopeptidaseactivitywasmonitoredfluorometricallyusing
either the FRET substrate Abz-AMESVMGYFHRSQ-EDDnp or
the fluorogenic substrate MeOSuc-AAPV-MCA. The fluorescence
intensity was monitored on a thermostatic Hitachi F-2500
spectrofluorimeter. The steady-state kinetic assays with fluorogenic
substrates were performed in 10 mM Hepes (pH 7.4) buffer
containing 140 mM NaCl and 0,05% Triton X-100 at 37uC. The
concentration of active HNE was determined by titration with the
irreversible chloromethylketone inhibitor MeO-Suc-AAPV-CH2Cl.
All reactions were done in 161 cm cross section quartz cuvette. For
MeOSuc-AAPV-MCA (0.02–1.00 mM) substrate assays, the exci-
tation and emission wavelengths were set at 380 and 460 nm,
respectively. For the FRET-peptide substrate (0.2–10 mM), the assay
wasconducted at 420 nmusing anexcitationwavelengthof320 nm.
The kinetic parameters were determined by measuring the initial
rate of hydrolysis at various substrate concentrations in presence and
or absence of heparin. The fluorescence of 7-amino-4-methylcou-
marin and ortho-aminobenzoic acid were determined for the
calculation of precise rateconstants. In order to calculate the
concentration of the released product calibration curves of
fluorescence versus concentration were constructed. The data
obtained were analyzed by nonlinear regression using the program
GraFit 3.01 (Erithacus Software Ltd.). The data were analyzed in
steady-state kinetic system and the values for the constants were
determined by using nonlinear regression to the hyperbolic tight-
binding equations as previously suggested [4]. The peptide bonds
cleaved in enzymatic reactions were determined by matrix-assisted
laser-desorption ionization-time-of-flight mass spectrometry (Tof-
Spec-E; Micromass, Manchester, U.K.).
Stopped-Flow Kinetic Analysis
Stopped-Flow fluorescence kinetic measurements were carried
outat25uCwithanSFM300mixingdevicefromBio-Logic(Pontde
Claix, France) equipped with two large (10 ml) syringes injecting
through the first mixer (S1)2 5ml of substrate and (S2) 365 mlo f
reaction buffer 10 mM Tris-HCl (pH 7.4) containing 100 mM
NaCl in presence or absence of heparin and a small syringe (S3;
2.5 ml) injectingthrough the second mixer 10 ml of HNE diluted in
the same buffer as that of the substrate. The injection time was
45 ms, (dead time of 3.1 ms). The signal recording was triggered at
the end of injection.The mixing device, equipped with an Fc15 flow
cell (1.5 mm61.5 mm cross section), was combined with the optical
bench and detection module of Bio-Logic. The incident wavelength
was setat 320 nm from a monochromator with a bandpass of 8 nm.
The emitted light was collected by a photomultiplier through a
350 nm high pass filter for Abz fluorescence measurements. The
signal was electronically processed in the Bio-Logic amplifier, and
finally converted into data files by means of the Bio-Kine software
package from Bio-Logic. In the experiments in the presence of
heparin the final concentrations were 3.8 mM FRET-peptide
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HNE. All the solutions were filtered and degassed immediately
before they were used.
Stopped-Flow Data analysis
The kinetic data were processed using DynaFit IV [23].
Regression analysis in DynaFit is performed by Reich’s variation
of the Levenberg–Marquardt least-squares fitting algorithm.
Convergence criteria are multiple in DynaFit: The Marquardt
parameter for individual parameters should be met first. This was
typically met within 100 iterations and 50 subiterations. Standard
errors of the individual parameters were computed from the square
roots of diagonal elements of the final variance–covariance matrix.
The protocol that gave individual rate constants and Michaelis–
Menten parameters were calculated from them, in agreement with
experimentally determined individual rate constants and experi-
mentally determined Michaelis–Menten parameters.
The fitting started with a three-step consecutive mechanism as
previously described [24]:
ES : k1,k{1)
ES0zP1 : k2
EzP2 : k2
From which the following differential equations were derived:
dE ½  =dt~{k1 E ½  S ½  zk{1 ES ½  zk3 ES0 ½  ð Eq:1Þ
dS ½  =dt~{k1 E ½  S ½  zk{1 ES ½  ð Eq:2Þ
DE S ½  =dt~zk1 E ½  S ½  {k{1 ES ½  {k2 ES ½  ð Eq:3Þ
dE S I  
dt~zk2 ES ½  {k3 ES0 ½  ð Eq:4Þ
dP 1 ½  =dt~zk2 ES ½  ð Eq:5Þ
dP 2 ½  =dt~zk3 ES0 ½  ð Eq:6Þ
The initial guesses were based on experimentally determined
values of kcat, which were used for the estimation of k2; the
concentration of enzyme and substrate were determined indepen-
dently. In a second round, k1, k21, k2 and k3 were optimized by
fitting for individual runs of 6,000 and 4,000 fluorescence time data
pairs, covering a total period of 6 and 4 sec, corresponding to
experimentsinabsenceand presenceofheparin,respectively,onthe
same three-step mechanism mentioned above [25]. From the three-
step reaction scheme, kcat~k2k3= k2zk3 ðÞ , KS~ k{1zk2 ðÞ =k1,
KM~KS k3= k2zk3 ðÞ ðÞ and kcat=KM~k1k2= k{1zk2 ðÞ were
calculated values [24]. The same kinetic constants calculation steps
described were used for the experiments in presence of large molar
excess of 50 mM heparin.
The kinetic events corresponding to heparin, HNE and
substrate reactions can be described by the model represented in
Scheme I.
Scheme I
/  
k-1zz
HH
Kd? KHd?
EH
/  
kh-1
zS  ?
kh1 { EHS  ?
kh2 { EHS0zP1  ?
kh3 { EHzP2
The influence of heparin upon HNE proteolysis of TIMP-1
TIMP-1 (3.1 mM) was incubated with 5.5 nM HNE in the
absence or in the presence 50 mM heparin for various periods of
time. The enzymatic reaction was performed in 100 mM Tris-
HCl buffer (pH 7.4) containing 100 mM NaCl and 0,05% Triton
X-100 at 37uC. Aliquots of both reaction mixtures were collected
at 20, 40, 60, 90 and 120 minutes and the reaction was stopped by
addition of PMSF to 0.1 mM final concentration in SDS-PAGE
sample buffer consisting of 200 mM Tris-HCl (pH 7.0) 4% SDS,
10% 2-mercaptoethanol, 20% glycerol, 0.025% bromphenol blue
(1:1 v/v) and finally boiled for 5 min. Samples were submitted to
12.5% SDS-PAGE and the products of TIMP-1 hydrolysis were
visualized by silver staining. TIMP-1 fragments were detected by
scanning densitometry.
HNE pH Activity Profile
For the determination of pH activity profiles, the kinetics of
FRET-peptide substrate hydrolysis were performed in absence or
in presence of 50 mM heparin at 37uC in four-component buffer
system of constant ionic strength, consisting of 25 mM glycine,
25 mM acetic acid, 25 mM Mes and 75 mM Tris, containing
140 mM NaCl and 0.05% (v/v) Triton X-100, the pH of buffers
were adjusted using HCl or NaOH diluted solutions. The
substrate concentrations were kept 20-fold below the KM values.
The progress of the reaction was continuously monitored by the
fluorescence of the released product. The initial rates were
determined, and the kcat/KM values were obtained by dividing the
initial rates by enzyme and substrate concentrations. It is
important to mention that the enzyme was stable at pH range
studied, and the pH values did not affect the ionic form of
substrate. The pH activity profiles data were fitted according to
Equation 7 by using non-linear regression software system (GraFit
version 3.0, Erithacus Software Ltd) as follows:
k~
kLimit
1z10 pKE1{pH ðÞ z10( pH{pKE2)
½Eq:7 
Equation 7 fits data when the pH-activity profile depends upon
two ionizing groups in a bell-shaped curve and the activities at low
and high pHsare zero; k~
kcat
KM
; kLimit stands for the pH-independent
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of a catalytically competent base and acid respectively.
Molecular Docking
PatchDock [26] was used to dock heparin to HNE complexed
with 1/2SLPI (Protein Data Bank ID 2Z7F). PatchDock is a fast
geometry-based docking algorithm that optimizes shape comple-
mentarily, used for an initial analysis of surface and atomic contact
variables, with no constraints used to define the initial binding site.
All docking simulations were performed using heparin di- and
octasaccharides. The octasaccharide has been modeled with the
iduronic acid at the non-reducing end in a
1H2 conformation and
the central and terminal iduronic acids in the
1C4 conformation,
and the disaccharide (IdoA,2S (1R4)GlcNS,6S) was extracted
from a heparin fragment (Protein Data Bank code 1HPN) [27,28].
Different docking simulations with iduronic acid in the
1C4 chair
conformation and the glucosamine in the
1C4 chair conformation
were performed in order to compare the docking results with those
obtained for a similar conformation of the octasaccharide.
Oligosaccharide structures were energy-minimized after addition
of hydrogen atoms to optimize the orientation of rotatable groups
and the surface area, contact energy, and binding score were
extracted from PatchDock. AutoDock4.0 was used as a grid based
docking procedure [29], defining a grid of 0.46 A ˚ and distance
dependent dielectric constant of 4.0 for the binding energy
calculations. The genetic algorithm with local search options (GA-
LS) as implemented in AutoDock was used to dock the flexible
heparin fragments, with 4500 search runs using an initial
population of 200 conformations. Hydroxyl groups were kept
fixed in order to maintain a maximum of 32 rotatable bonds, and
the grid box and constant grid spacing of 0.46 A ˚ around each
heparin fragment binding were obtained from PatchDock with
respect to HNE.
The FRET-peptide docking was built using PRODRG2 [30],
with Gasteiger charges [31] calculated using Autodock tools
[http://www.scripps.edu/ ˜sanner/python/adt/]. Lamarckian ge-
netic algorithm, with 2.5610
8 energy evaluations (high) and 200
generations with step sizes of 0.2 for translation and 5.0 for
quaternion and torsion, respectively, was employed. The best-
docked conformers with lowest free energies (214 kcal/mol)
conformations were taken for further analysis.
Results
Effect of Heparin on the Proteolytic Processing of TIMP-1
by HNE
It has been shown that HNE is able to cleave TIMP-1 at the
Val
69-Cys
70 bond [16]. Since heparin and HSPG can modulate
the activity of HNE, weexamined whether heparin modified the
proteolysis of TIMP-1 by HNE. Figure 1 shows a SDS-PAGE
image analyzing the proteolytic processing of TIMP-1 by HNE in
the absence or in the presence of 50 mM heparin. The efficiency of
TIMP-1 cleavage by HNE in the presence or in the absence of
heparin was indicated by the appearance of the 14 kDa and
16 kDa fragments [16]. Scanning densitometry of time course
experiments indicated that heparin increased 2.5-fold the initial
rate of TIMP-1 14 kDa and 16 kDa fragments released by HNE
(Fig. 1B). This result is very interesting and it was not expected
since heparin [3,4] and other natural polyanionic polymers such as
DNA [32] and alginate [33] have been described in the literature
as inhibitors of HNE.
Effect of Heparin upon the HNE Endopeptidase Activity
In order to better study the mechanism of heparin action on the
hydrolysis of TIMP-1 by HNE, we synthesized a FRET-peptide
Abz-AMESVMGYFHRSQ-EDDnp that mimics the primary
sequence of TIMP-1 between residues 65-76 [16]. The HPLC
and Maldi-TOF mass spectrometry analysis showed that Val-Met
is the only peptide bond cleaved by HNE on this substrate. This
FRET-peptide substrate covers the HNE subsites from S5 to S’5
according to the Schechter & Berger nomenclature [34], which are
the main substrate binding sites in HNE [2]. The presence of
heparin did not change the pattern of cleavage of this peptide by
HNE. The specificity observed in this cleavage is in agreement
Figure 1. Heparin up-regulates TIMP-1 proteolysis by HNE. A, TIMP-1 (220 mg/ml) was allowed to react with 0.55 mg/ml HNE at 37uCi n
absence (lanes 1, 2, 4, 6, 8 and 10) or in presence (lanes 3, 5, 7, 9 and 11) of 50 mM heparin. The reaction was performed in 100 mM Tris-HCL, pH 7.4,
containing 100 mM NaCl, and 0,05% Triton X-100. Aliquots from both samples were collected at 20, 40, 60, 90 and 120 minutes and the reaction was
stopped by inactivation of HNE with PMSF. TIMP-1 fragments were analyzed by SDS-PAGE under reducing conditions and visualized by silver staining.
B, the extent of TIMP-1 cleavage in the presence (N) or in the absence of heparin (&) is plotted as a function of time of reaction with HNE after gel
densitometry.
doi:10.1371/journal.pone.0021525.g001
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tially occupied by short hydrophobic residues such as Val, Ala, Ile
and Met [2,35]. Also, it is important to mention that no interaction
between FRET-peptide substrate with heparin was detected by
studying the intrinsic fluorescence of FRET-peptide in function of
heparin concentration (data not shown).
The binding of heparin to HNE perturbs its catalytic activity
upon FRET-peptide substrate (Fig. 2). The efficiency of the
system for the hydrolysis of FRET-peptide can be altered
by changing either KM value (a parameter) or kcat value
(b parameter). Figure 2 shows that the presence of heparin
results in a large increase in kcat value (b=4.660.2) but also a
marked decrease of the affinity of the enzyme for the FRET-
peptide substrate as reflected by the strong increase of the KM
value (a=2.060.1). The catalytic efficiency (b/a ratio) for this
substrate in the presence of heparin thus increased 2.5-fold.
Likewise, at high substrate concentration, the dissociation
constant of HNE for heparin is increased 2.0-fold. It was
observed that heparin binds tightly to free HNE (E) and to the
enzyme-substrate complex (ES) with dissociation constants KH
and aKH of 661 nM, and 1461 nM respectively. It was observed
that heparin regulates HNE endopeptidase activity upon the
substrate Abz-AMESVMGYFHRSQ-EDDnp by a tight-binding
hyperbolic mixed type reaction as depicted in Scheme I.
Curiously, heparin showed a different pattern of HNE
inhibition when assayed with the fluorogenic substrate MeO-
Suc-AAPV-MCA. The effects of heparin upon the HNE
hydrolysis of this substrate can be described by a tight-binding
hyperbolic mixed-type inhibition model. Indeed, the data could
be well fitted to an equation that describes this inhibition
behavior [4] by using non linear regression, provided the values
for the constants shown in Table 1. The presence of heparin in
the HNE kinetic assays also results in 2.5 fold increase of the KM
value for the hydrolysis of the substrate MeOSuc-AAPV-MCA.
On the other hand, heparin induced a small decrease in the
catalytic constant (kcat) of HNE for the hydrolysis of this
substrate. Interestingly, Spencer at al. [4] have shown that
inhibition of HNE hydrolysis of the substrate MeOSuc-AAA-
pNA by various heparin compounds follows a tight-binding,
partial competitive mechanism (a=3.460.3, b=0.9660.05).
The conjunction of these and our data strongly suggest that the
effect of heparin on HNE activity is very dependent on the
substrate structure.
Although the three-step mechanism for HNE-catalyzed hydro-
lysis of peptides is widely accepted [36], the individual rate
constants that describe the steps have not been determined in the
studies of HNE’s inhibition. Sincekcat~k2k3= k2zk3 ðÞ andKM~
Ks k3= k2zk3 ðÞ ðÞ are composites parameters of the rate constants,
the Michaelis-Menten kinetic parameters kcat and KM, determined
by steady-state analysis do not give a detailed picture about the
kinetic mechanism of HLE inhibition by heparin [24]. Clearly, the
only way to get an accurate picture of HNE inhibition by heparin
is through the determination of heparin effect upon the
mechanistic kinetic parameters k1, k21, k2 and k3.
Figure 2. The effect of heparin on steady-state FRET-peptide hydrolysis by HNE. The influence of heparin concentration upon steady-state
HNE kinetics parameters kcat [A] and KM [B] was determined spectrofluometricallyas described under ‘‘Experimental Procedures’’. The fluorescence
increase of FRET-peptide hydrolysis (0.2 - 10 mM) by 12.6 nM HNE were performed in 10 mM Hepes, pH 7.4, containing 140 mM NaCl and 0,05%
Triton X-100 at 37uC.
doi:10.1371/journal.pone.0021525.g002
Table 1. Steady-state kinetic parameters for hydrolysis of
fluorogenic substrates by human neutrophil elastase in the
presence of heparin.
Substrate
KM
(mM)
kcat
(s
21)
kcat/KM
(mM
21s
21)
a
(KM
ap/
KM)
b
(kcat
ap
/kcat)
FRET-peptide
Control 1.660.1 0.5660.06 350640
Heparin 3.160.3 2.5060.20 810660 2.0 4.46
MeOSuc-AAPV-MCA
Control 138616 16.861.2 10669
Heparin 389640 10.460.9 2764 2.8 0.62
MeOSuc-AAA-MCA
a
Control 1610630 0.3660.02 0.22860.003
Heparin 5940612 0.3660.02 0.06160.001 3.5 0.96
aReference [4].
doi:10.1371/journal.pone.0021525.t001
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Hydrolysis by HNE
The kinetics of the FRET-peptide substratehydrolysis by HNE
was also conducted in a stopped-flow fluorescence apparatus in the
absence or in the presence of 50 mM heparin. Figure 3A shows that
in the absence of heparin, the cleavage of the FRET-peptide
substrate Abz-AMESVMGYFHRSQ-EDDnp by HNE exhibited
an initial burst of product formation, strongly suggesting the
existence of a rate-limiting step after acyl-enzyme formation
[24,37]. The observation of such a burst under pre-steady
conditions is typical of a rate-limiting deacylation (k3) in amide
hydrolysis [36].
In order to determinethe valuesfor thekinetic constantsk1, k-1, k2
and k3 of the FRET-peptide hydrolysis by HNE, the kinetic data
from progress curves were processed using DynaFit IV software as
previously described. Table 2 shows that the hydrolysis of FRET-
peptide by HNE can be satisfactorily described by a three-step
kinetic mechanism, where KS=(k-1+k2)/k1 stands for the formation
of HNE-FRET-substrate complex, k2 stands for the HNE acylation
step and k3 stands for the HNE deacylation step [24]. As expected,
the value of k2 (2161s
21) was much higher than the value of k3
(0.5760.05 s
21) and the kcat constant is practically governed by k3,
these values agree with the observation of burst of product
formation in the initial step of HNE reaction. Because k2
(2161s
21) is much higher than k21 (0.2560.02 s
21), the hydrolysis
ofFRET-peptidesubstratebyHNEis adiffusioncontrolled process;
theconstant of specificitykcat/KM is governed bythe associationrate
constant k1 (0.3560.03 mM
21.s
21). Moreover, as k2 is largely higher
than k21, KM (1.660.01 mM) cannot be considered a true
dissociation constant. These results show that the HNE mainly
exists as an acyl-enzyme (71%) in the steady-state during the
hydrolysis of this FRET-peptide (Fig. 3B).
We were interested in whether heparin could influence the pre-
steady-state behavior of the HNE. Interestingly, the presence of
heparin induces a dramatic effect in the pre-steady-state behavior
of the enzyme. As shown in Figure 4A, heparin induces a transient
lag phase in HNE cleavage of FRET-peptide substrate (Fig. 4A).
The presence of heparin thus resulted in the loss of the burst in
HNE cleavage of FRET-peptide substrate,indicating that deacyla-
tion was no longer rate-limiting. The steady-state observed
stimulation of HNE cleavage of FRET-peptide substrate by
heparin indicates that heparin binding must stimulate the formerly
rate-determining deacylation step. Indeed, heparin promotes a
7.8-fold decrease in k2 value, whereas the k3 value in the presence
of heparin was increased 58-fold (Table 2). These results clearly
show that heparin binding accelerates deacylation and slows
acylation. Fig. 4B shows that in the steady state, in the presence of
heparin, HNE mainly exists as free-enzyme, EH (49.5%) and non-
Figure 3. Stopped-flow time-tracesofFRET-peptidehydrolysis by HNE. A, Stopped-flow fluorescence kinetic recording of 3.8 mMFRET-
peptide hydrolysis by 12.6 nM HNEat 25uC in 10 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl. The progress of the reaction was monitored by
the fluorescence increase of the released product recorded on 2 adjacent time regions with distinct sampling periods: 0.5 ms from 0 to 2 s, 2 ms from
2 to 6 s. Gray solid line represents the best fit obtained from the mechanism depicted in Scheme I in the absence of heparin with the aid of DynaFit
IVH software (see Experimental Procedures). The insert graphic represents the associate residual errors from the best fit curve with experimental data.
B, the HNE species as a function of time reaction: free enzyme, E (–); complex enzyme-substrate, ES (– N–) and acyl-enzyme, ES’ (--- ).
doi:10.1371/journal.pone.0021525.g003
Table 2. Effect of heparin on pre-steady-state kinetic parameters for hydrolysis of FRET-peptide substrate by human neutrophil
elastase.
Conditions
k1.10
6
(M
21s
21)
k21
(s
21)
k2
(s
21)
k3
(s
21)
KM
a
(mM)
kcat
b
(s
21)
FRET-peptide
Control 0.3560.03 0.2560.02 2161 0.5760.05 1.660.1 0.5660.06
Heparin 0.8260.06 0.08160.005 2.760.2 33623 . 1 60.3 2.560.2
aKM~k3 k{1zk2 ðÞ =k1 k2zk3 ðÞ and
bkcat~k2k3= k2zk3 ðÞ [36].
doi:10.1371/journal.pone.0021525.t002
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condition only 0.5% of the HNE exists in the acylenzyme form
(EHS’).
Heparin accelerates the hydrolysis of FRET-peptide by NHE;
kcat value is increased 4.5-fold in the presence of heparin.
However, heparin also induces an increase of 2.0-fold in KM
value; the catalytic efficiency kcat/KM for this substrate in the
presence of heparin is 2.3-fold increased. As mentioned above,
heparin promotes a marked decrease of k2 (7.8 fold). It also
decreases k-1 by 3-fold. Since in the presence of heparin k2 is
largely greater than k-1, while k1 is slightly increased, the catalytic
efficiency in the presence of heparin appears mainly limited by Ks,
the equilibrium dissociation constant of the non covalent complex
ES.
It has been suggested that when an enzyme reaction is diffusion
controlled, the conformation and solvation of the substrate and
enzyme will determine the rate of substrate association, and hence
the specificity [38]. Our results suggested that the notable heparin-
induced increase in catalytic efficiency of HNE might be due to a
conformational change of the enzyme resulting in a change of the
intrinsic kinetic characteristics.
The Influence of Heparin upon the HNE pH Activity
Profile
The effect of heparin on the pH activity profiles of HNE was
analyzed by monitoring the enzyme-catalyzed hydrolysis of the
Abz-AMESVMGYFHRSQ-EDDnp substrate. Figure 5 shows
that HNE displays bell-shaped pH dependence both in the
absence and presence of heparin. When HNE was assayed in the
presence of 50 mM heparin a dramatic effect of heparin was
observed upon the pH-activity profile. Basically, heparin promot-
ed a general increase of about 2.5-fold in the values of kcat/Km
observed for FRET-peptide substrate hydrolysis and shifted the
Figure 4. Stopped-flow time-traces  of  FRET-peptidehydrolysis by HNE in the presence of heparin. A, the stopped-Flow fluorescence
kinetic recording of 3.8 mMFRET-peptide hydrolysis by 12.6 nM HNEperformed at 25uC in 10 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl
supplemented with 50 mM heparin. The progress of the reaction was monitored by the fluorescence increase of the released product recorded on
two adjacent time regions with distinct sampling periods: 0.5 ms from 0 to 2 s, 2 ms from 2 to 4 s. Gray solid line represents the best fit deduced
from the mechanism depicted in Scheme I in the presence of heparin using DynaFit IVH Software [see Experimental Procedures]. The insert graphic
represents the associate residual errors from the best fit curve with experimental data. B, the HNE species in function of time reaction in presence of
heparin: complex enzyme-heparin, EH (–); complex enzyme-substrate-heparin, ESH (– N–) and complex acyl-enzyme-heparin, ES’H (--- ).
doi:10.1371/journal.pone.0021525.g004
Figure 5. The effect of heparin onHNE pH activity profile. The
kinetics of FRET-peptide hydrolysis by HNE were performed as a
function of pH in the absence (N) or in the presence (#)o f5 0mM
heparin at 37uC. The FRET-peptide hydrolysis wasmonitored continu-
ously by the fluorescence of the released product (for experimental
details, see the Experimental Procedures section).
doi:10.1371/journal.pone.0021525.g005
Table 3. Effect of heparin upon the ionization constants of
prototropic groups from the human neutrophil elastase active
site.
Parameters Control Heparin
pK1 6.7160.05 7.0460.07
kcat/KM(mM
21s
21) 0.3960.02 1.1160.05
pK2 8.9360.05 9.6060.07
pH optimum 7.8260.05 8.3260.07
doi:10.1371/journal.pone.0021525.t003
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shows that in the presence of heparin the value of pKE1 was shifted
from 6.7 to 7.0, the pKE2 was increased from 8.9 to 9.6, and the
pHopt of HNE was increased from 7.8 to 8.3. These results clearly
show that the presence of heparin allows HNE to be active at
alkaline pH.
The acidic pK (pKE1 of about 6.7 or 7.0) presumably results from
deprotonation ofHis57, whilethe basicpK (pKE2ofabout8.9or9.6)
would result from deprotonation of Ile16 [39]. pKE2 is an apparent
pKa determined both by the ionization constant of the free a-amino
group and by the conformational equilibrium between the active
(salt bridge formed) and inactive (saltbridgedissociated) formsofthe
protease. The salt bridge Ile16-Asp194 is formed when the inactive
proenzyme is converted to active enzyme by the proteolytic
cleavage of a peptide from the N-terminus. Formation of this salt
bridge triggers a conformational change in the ‘‘activation domain’’
of trypsin-like enzymes, creating the S1 binding site and oxyanion
hole of serine proteases [36,40].
Molecular Docking Analysis
Molecular docking of heparin and the FRET-peptide was
performed using the crystal structure of the HNE [41], assuming
that the minimum energy represents the best model for the peptide
binding site. Figures 6A and C show the optimal docking site for
the FRET-peptide. It indicates that, as expected, the subsites P1
and P1’ of HNE are occupied by Val and Met residues respectively
from the FRET-peptide [42]. The carbonyl group of theMet from
the substrate is at a 1.21 A ˚ distance from the NH group of the
catalytic S195, and the NH group of the Met from the substrate is
at a 1.074 A ˚ distance from the CO group of F41 (Table 4). The
F41 residue of HNE is in the vicinity of the S1’-S2’ substrate
binding sites [42]. The CO group of the Tyr residue from the
FRET-peptide substrate is within 2.14 A ˚ from the NH group of
the catalytic His57 residue (Table 4). In this model, the 2-O-sulfate
group from the Idu3 residue of heparin is within 2.4 A ˚ from the
carbonyl group of Val216 (Fig. 6B), which is found in subsite P3 of
HNE [42]. Heparin interacts with the NH group of Met at S1’
(Fig. 6D) and it also perturbs the interaction of Tyr with His 57 at
S3’ (Table 4). These data indicate that heparin interacts with the
substrate binding site that extends from at least subsites S3 to S3’
(Fig. 6B). In the presence of heparin, the distance from the Met
carbonyl group of the substrate to the NH group of the catalytic
S195 was increased from 1.21 to 6.12 A ˚ (Table 4). As previously
mentioned, the pre-steady-state analysis shows that heparin was
able to decrease 7.8-fold the HNE acylation rate (k2) of FRET-
peptide substrate (Table 2). Taken together, these data suggest that
heparin is decreasing the rate of the acylation step of HNE by
increasing the distance of the catalytic S195 residue to the
carbonyl group of the cleavable amide bond, disturbing the
nucleophilic attack of the catalytic serine on the carbonyl group of
Met at S1’.Docking analysis of the heparin with free HNE suggests
that the heparin is in contact with arginine residues at R36, R75,
R76, R80, R177 and R217 (Fig.6B), as previously suggested [4].
On the other hand, in the presence of the substrate, heparin
preferentially interacts with HNE at R36, R75, R76, R80, R147
and R149 (Fig. 6D).The theoretical constant of equilibrium
obtained for the binding of heparin to HNE is 1.7 nM at 37uC
based on the free energy ((G~{R:T:ln K;eq ). This value is
very close to the experimental value of the equilibrium constant
(Kd=361 nM), as previously determined for the interaction of
heparin with HNE [7]. The docking energy for the FRET-peptide
with HNE was 26.6 kcal/mol at 25uC (Fig. 6C). However, in the
presence of heparin, the docking energy for the substrate binding
to HNE was only 21.3 kcal/mol (Fig. 6D); these data indicate that
heparin binding is favoring the release of both the substrate and
product from the HNE active site, as previously shown by the data
reported in Table 2.
Discussion
It had been shown that HNE undergoes inhibition by heparin
and related glycosaminoglycans by a tight-binding, electrostatically
driven, hyperbolic mixed-type inhibition mechanism with a
predominantly competitive character [4]. However, this inhibitory
effect upon HNE activity is reversed and even abolished at high
concentrationsoftheglycosaminoglycans[43].The inhibitory effect
of heparin and other polysulfated GAGupon HNEactivity seemsto
be circumstantial rather than consensual and is likely related to both
substrate structure [44] and inhibitor concentration [43].
Figure 6. Representation of the complex of both FRET-peptide
and heparin with HNE. A, Docking of HNE with the substrate
AMESVMGYFHRSQ,the secondary structure elements of the HNE are
represented by indigo blue schematics (arrows for extended strands, and
cylinders for helices).The carbon atoms of the substrate are indicated by
a green sticks, view of the minimum energy conformation from docking,
showing the substrate labeled at P1Val and P1’Met completely engulfed
inside the HNE active site cavity: S195, H57 and D103 (dark blue for
nitrogen atoms, light yellow for carbon atoms, red for oxygen atoms,
grey for hydrogen atoms and dark yellow for sulfur). HNE active site
residues are labeled following the numbering of chymotrypsin.
B, Docking of HNE with heparin,the secondary structure elements of
the HNE are represented by green schematics (arrows for extended
strands, and cylinders for helices) and the catalytic residues of the HNE
are labeled.The carbon atoms of heparin chain are indicated by a cyan
sticks and its sulfur atoms are indicated by dark yellow. C, Enlarged view
of the HNE catalytic residues S195, H57 and D103 with substrate labeled
at P1Val and P1’Met. D, Stereo view of the ternary complex between
HNENHeparinNSubstrate, the secondary structure elements of the HNE
are represented by green schematics. The carbon atoms of the substrate
are indicated by a cyan sticks and the carbon atoms of heparin are
indicated by magenta sticks.
doi:10.1371/journal.pone.0021525.g006
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TIMP-1 hydrolysis by HNE (Fig. 1). The magnitude of the effect of
heparin on the rate of TIMP-1 hydrolysis by HNE is basically the
same as the heparin-induced increase of FRET-peptide hydrolysis
(Fig. 2). In both cases heparin increases 2.5-fold the hydrolysis of the
substrates by HNE. Taken together, these results show that heparin
binding is perturbing both HNE substrates hydrolysis in a similar
manner. This fact is not an isolated case, since it can be found in the
literature that heparin greatly activates a specific and limited
proteolytic cleavage of the serpin antithrombin III [ATIII] by HNE
[45,46]. More, heparin and dermatan sulfate accelerated the
inactivation rate of the serpin heparin cofactor II [HC II] by
neutrophil elastase [47].
Seminal works of Stein et al [21,34,48] have shown that the
steady-state kinetic parameters kcat, KM,a n dkcat/KM do not give a
clear picture of HNE’s substrate specificity, because kcat~
k2k3= k2zk3 ðÞ andKM~KS k3= k2zk3 ðÞ ðÞ are composite parame-
ters of the intrinsic rate constants. That the determination of the
steady-state parameters is not sufficient to describe the kinetic
mechanism is particularly obvious in the case of HNE inhibition by
heparin.Here, we have shown that HNE exhibits pre-steady-state
burst behavior in cleavage of the FRET-peptide substrate related to
TIMP-1 sequence (Fig.3). As expected, the acylation rate (k2) for
HNE cleavage of the FRET-peptide Val-Met bond is substantially
higher than deacylation (k3), the product release step. Fig. 3B shows
that such behavior reduces the concentration of free enzyme; HNE
in steady-state is 71% sequestered in the acyl-enzyme intermediate.
TheslowrateofdeacylationofFRET-peptidesuggeststhatTIMP-1
can be considered a bad substrate for HNE hydrolysis.
The advantage conferred in vivo by the rate-limiting deacylation
seen with HNE may be not yet apparent. This pre-steady-state
behaviorreducestheconcentrationoffree enzymemainlywhen this
potent proteolytic enzyme is secreted to the pericellular environ-
ment, thereby lowering the rate of cleavage of substrates at cell
surface and extracellular matrix. Similar pre-steady-state behavior
has been observed for Kex2 protease and furin, these enzymes are
thus thought to accumulate the acyl-enzyme intermediate at the
steady state in vivo also [49]. It is possible that slow rate of
deacylation of TIMP-1 maintains the rate of incorrect cleavage
below some toxic threshold, or it may serve as a means of
maintaining a reserve pool of protease as a sequestered acyl-enzyme
intermediate, since HNE is in excess in vivo [1]. However, such a
reserve population would only be advantageous if there were some
means of mobilizing it to active form of HNE [50]. In agreement
with this scenario, we have observed that heparin (Fig. 4) can
stimulatekcatby increasingthe deacylationrateforHNEcleavage of
TIMP-1 substrate.
The presence of heparin resulted in a loss of burst kinetics in
HNE cleavage of FRET-peptide substrate (Fig.4); heparin alters
the pre-steady-state behavior of HNE not only by accelerating
deacylation but also in slowing down acylation rates (Table 2). The
pre-steady-state analysis revealed that heparin affects all steps of
the reaction: (i) it enhances the ES complex formation, by
increasing 2.4-fold k1 and reducing 3.1-fold k-1, (ii) it strongly
affects the acyl-enzyme accumulation with pronounced decrease in
k2 (7.8-fold), and increase in k3 (58-fold). The present data suggest
that heparin is capable of altering the conformation of the HNE to
permit more rapid association with TIMP-1 or FRET-peptide
substrate [51]. However, our data do not exclude the possibility
that heparin can stabilize a ternary complex between HNENHepN-
TIMP-1 by interacting with HNE and TIMP-1 simultaneously
(Fig. 6 D). It has been shown that heparin interacts with the netrin-
like domain at the N-terminal region of TIMPs [52].
The effect of heparin towards HNE pH activity profile also
suggests allostery as a major aspect of the regulation of HNE
(Fig.5).Basically, heparin shifted the HNE pH activity profile about
0.5 units to the right. Table 3 shows that in the presence of heparin
the value of pKE1 was shifted from 6.7 to 7.0, the pKE2 was
increased from 8.9 to 9.6 and the pHopt of HNE was increased
from 7.8 to 8.3. These results clearly show that heparin shifts the
HNE pH activity profile to the right, allowing HNE to be active at
alkaline pH. More, the data also show that the binding of heparin
to HNE perturbs the ionization of the reactive imidazolium group
of His57 (pKE1), this residue mediated general basis catalysis of
serine proteases [53].
The high affinity of heparin for HNE [13], Kd=3 nM, is a
relevant matter since it results in an increase of HNE activity
towards TIMP-1. A previous study presented by Owen and co-
workers [9,10] showed that HLE binds to soluble high Mr heparan
sulfate proteoglycans (HSPG) shed into bronchial secretions from
Table 4. Molecular Docking Analysis.
Predicted Interactions of the HNE binding site residues with the FRET-peptide substrate
HNE Peptide contact Distance [A ˚] Angle [u]
F41 - CO P1’-Met - NH 1.074 144.8
S195 - NH P1’-Met - CO 1.21 127.2
H57 - NH P3’ - Tyr - CO 2.14 117.3
Predicted Interactions of the FRET-peptide residues with Heparin
AMESVMGYFHRSQ Heparin
P1’-Met - NH GlcNS3 - 2-N-SO3- 2.85 121.4
V216 - CO IduS3 -2-0-SO3- 2.4 114.9
Predicted Interactions of the HNE binding site residues with the FRET-peptide substrate after Heparin docking
HNE Peptide contact Distance [A ˚] Angle [u]
F41 - CO P1’-Met - NH 2.74 144.8
S195 - NH P1’-Met - CO 6.12 127.2
H57 - NH P3’- Tyr - CO 7.38 117.3
doi:10.1371/journal.pone.0021525.t004
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fluids [8,11], retaining its catalytic activity against extracellular
matrix substrates. Thus, binding of HNE to HSPG in neutrophil
plasma membranes does not significantly compromise its catalytic
activities. In this case, the major difference between the soluble
and membrane-bound forms of the elastase is its susceptibility to
serine proteinase inhibitors, in which the membrane-bound HLE
on activated neutrophil are remarkably resistant to inhibition by
physiologic inhibitors [8–10].
The large amounts of proteoglycans and free chains of GAG
present in the extracellular matrix can overcome the slow rate of
deacylation of TIMP-1 hydrolysis, thereby increasing the amount
of TIMP-1 processed by HNE. Indeed, MMP-9/TIMP-1
imbalance has been observed in sputum of patients with cystic
fibrosis [17] and in abdominal aortic aneurysm [19]; where the
high level of HNE promotes a large MMP-9 activation either
directly or by the proteolysis of TIMP-1, its natural inhibitor.
TIMP-1 is essential to protected against blood-brain barrier
disruption after ischemic stroke by regulating activities of MMPs
[54]. Increased MMP-9 activity is also observed in bone resorption
state [20]. Interesting, the major clinical complication of heparin
anticoagulant therapy is bleeding, heparin administration can
promote hemorrhage complications [55] and osteoporosis by
increasing bone resorption [56] as side effects. Heparin was
associated with a dose-dependent increase of both intracranial and
extracranial bleeding [57]. It has been shown that heparin can
produce intracranial hemorrhage dependent of MMP-9 activity
[58]. Heparin increases eight-fold the initial rate of proMMP-9
autolytic activation [59]. Here, we are showing for the first time
that heparin accelerates 2.5-fold the rate of the TIMP-1 hydrolysis
by HNE. Taken together, these data are strongly suggesting that in
the presence of heparin a large amount of active MMP-9 is
available. These data may have important clinical implications,
since the most important adverse effects of heparin are related to
excessive activation of MMP-9.
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